Alfentanil is filed as Opioid analgesic. The sections below restate public label fields stored for this profile.
1 INDICATIONS AND USAGE Alfentanil Injection is indicated: • as an analgesic adjunct given in incremental doses in the maintenance of anesthesia with barbiturate/nitrous oxide/oxygen. • as an analgesic administered by continuous infusion with nitrous oxide/oxygen in the maintenance of general anesthesia. • as a primary anesthetic agent for the induction of anesthesia in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required. • as the analgesic component for monitored anesthesia care (MAC). Alfentanil Injection is an opioid indicated:( 1 ) • as an analgesic adjunct given in incremental doses in the maintenance of anesthesia with barbiturate/nitrous oxide/oxygen. • as an analgesic administered by continuous infusion with nitrous oxide/oxygen in the maintenance of general anesthesia. • as a primary anesthetic agent for the induction of anesthesia in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required. • as the analgesic component for monitored anesthesia care (MAC).
12.1 Mechanism of Action Alfentanil Injection is an opioid agonist. The principal actions of therapeutic value are analgesia and sedation.
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ALFENTANIL INJECTION Addiction, Abuse, and Misuse Because the use of ALFENTANIL INJECTION exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of ALFENTANIL INJECTION, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ALFENTANIL INJECTION are essential [see Warnings and Precautions (5.2) ] . Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of ALFENTANIL INJECTION and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3) , Drug Interactions (7) ] . Cytochrome P450 3A4 Interaction The concomitant use of ALFENTANIL INJECTION with all cytochrome P450 3A4 inhibitors may result in an increase in alfentanil plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in alfentanil plasma concentration. Monitor patients receiving ALFENTANIL INJECTION and any CYP3A4 inhibitor or inducer [s ee Warnings and Precautions (5.4) , Drug Interactions (7) , Clinical Pharmacology (12.3) ] . WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ALFENTANIL INJECTION See full prescribing information for complete boxed warning. • ALFENTANIL INJECTION exposes users to the risks of addiction, abuse, and misuse. Assess patient’s risk before prescribing and reassess regularly for the development of these behaviors and conditions ( 5.1 ). • Serious, life-threatening, or fatal respiratory depression may occur with use of ALFENTANIL INJECTION, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ALFENTANIL INJECTION are essential (5.2) . • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate (5.3) , (7) . • Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of alfentanil (5.4) , (7) , (12.3) .
5 WARNINGS AND PRECAUTIONS • Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, and Debilitated Patients : Monitor closely, particularly during initiation and titration. ( 5.2 ) • Risks of Muscle Rigidity and Skeletal Muscle Movement : Manage with neuromuscular blocking agent. See full prescribing information for more detail on managing these risks. ( 5.5 ) • Opioid-Induced Hyperalgesia and Allodynia : Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. If OIH is suspected, carefully consider appropriately decreasing the dose of the current opioid analgesic or opioid rotation. ( 5.6 ) • Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue Alfentanil Injection if serotonin syndrome is suspected. ( 5.7 ) • Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, and Head Injury : Monitor for sedation and respiratory depression. ( 5.10 ) 5.1 Addiction, Abuse, and Misuse Alfentanil Injection contains alfentanil, a Schedule II controlled substance. As an opioid, Alfentanil Injection exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9) ]. Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when handling Alfentanil Injection. Strategies to reduce these risks include proper product storage and control practices for a C-II drug . Contact local and state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product. 5.2 Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Alfentanil Injection should be administered only by persons specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, including respiration and cardiac resuscitation of patients in the age group being treated. Such training must include the establishment and maintenance of a patent airway and assisted ventilation. Adequate facilities should be available for postoperative monitoring and ventilation of patients administered anesthetic doses of Alfentanil Injection. It is essential that these facilities be fully equipped to handle all degrees of respiratory depression. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see Overdosage (10) ] . Carbon dioxide (CO 2 ) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. As with other potent opioids, the respiratory depressant effect of Alfentanil Injection may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered by the practitioner before ordering opioid analgesics during recovery from anesthesia. Certain forms of conduction anesthesia, such as spinal anesthesia and some epidural anesthetics, can alter respiration by blocking intercostal nerves [see Clinical Pharmacology (12.2) ] . Alfentanil Injection can also alter respiration. Therefore, when Alfentanil Injection is used to supplement these forms of anesthesia, the anesthetist should be familiar with the physiological alterations involved, and be prepared to manage them in the patients selected for these forms of anesthesia. Patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Alfentanil Injection. Elderly, cachectic, or debilitated patients may have altered pharmacokinetics or altered clearance compared to younger, healthier patients resulting in greater risk for respiratory depression. Monitor such patients closely including vital signs, particularly when initiating and titrating Alfentanil Injection and when Alfentanil Injection is given concomitantly with other drugs that depress respiration. To reduce the risk of respiratory depression, proper dosing and titration of Alfentanil Injection are essential [see Dosage and Administration (2) ] . Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage and Administration (2.1) ]. 5.3 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants When benzodiazepines or other CNS depressants are used with Alfentanil Injection, pulmonary arterial pressure may be decreased. This fact should be considered by those who conduct diagnostic and surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient. When high dose or anesthetic dosages of Alfentanil Injection are employed, even relatively small dosages of diazepam may cause cardiovascular depression. When Alfentanil Injection is used with CNS depressants, hypotension can occur. If it occurs, consider the possibility of hypovolemia and manage with appropriate parenteral fluid therapy. When operative conditions permit, consider repositioning the patient to improve venous return to the heart. Exercise care in moving and repositioning of patients because of the possibility of orthostatic hypotension. If volume expansion with fluids plus other countermeasures do not correct hypotension, consider administration of pressor agents other than epinephrine. Epinephrine may paradoxically decrease blood pressure in patients treated with a neuroleptic that blocks alpha adrenergic activity [see Drug Interactions (7) ] . Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Alfentanil Injection with benzodiazepines and/or other CNS depressants including alcohol (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids). Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics [see Drug Interactions (7) ] . If the decision is made to manage postoperative pain with Alfentanil Injection concomitantly with a benzodiazepine or other CNS depressant, start dosing with the lowest effective dosage and titrate based on clinical response. Monitor patients closely for signs and symptoms of respiratory depression, sedation, and hypotension. Fluids or other measures to counter hypotension should be available. [see Drug Interactions (7) ] 5.4 Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of Alfentanil Injection with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of Alfentanil Injection and prolong opioid adverse reactions, which may exacerbate fatal respiratory depression [see Warnings and Precautions (5.5) ] , particularly when an inhibitor is added after a stable dose of…
4 CONTRAINDICATIONS Alfentanil Injection is contraindicated in patients with: • Hypersensitivity to alfentanil (e.g., anaphylaxis) [see Adverse Reactions (6) ] Hypersensitivity to alfentanil. ( 4 )
Apnea (Most common); Rigidity (Most common); Bradycardia (Most common)
6 ADVERSE REACTIONS The following serious adverse reactions are described, or described in greater detail, in other sections: • Addiction, Abuse, and Misuse [see Warnings and Precautions (5.1) ] • Life-Threatening Respiratory Depression [see Warnings and Precautions (5.2) ] • Muscle Rigidity and Skeletal Muscle Movement [see Warnings and Precautions (5.5) ] • Opioid-Induced Hyperalgesia and Allodynia [see Warnings and Precautions (5.6) ] • Interactions with Benzodiazepines and CNS Depressants [see Warnings and Precautions (5.3) ] • Serotonin Syndrome [see Warnings and Precautions (5.7) ] • Bradycardia [see Warnings and Precautions (5.9) ] • Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.11) ] • Seizures [see Warnings and Precautions (5.12) ] Most common adverse reactions were apnea, rigidity, and bradycardia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following adverse reaction information is derived from controlled and open clinical trials in 785 patients who received intravenous Alfentanil Injection during induction and maintenance of general anesthesia. The controlled trials included treatment comparisons with fentanyl, thiopental sodium, enflurane, saline placebo and halothane. The incidence of certain side effects is influenced by the type of use, e.g., chest wall rigidity has a higher reported incidence in clinical trials of Alfentanil Injection induction, and by the type of surgery, e.g., nausea and vomiting have a higher reported incidence in patients undergoing gynecologic surgery. The overall reports of nausea and vomiting with alfentanil were comparable to fentanyl. Incidence Greater than 1% - Probably Causally Related (Derived from clinical trials) Gastrointestinal: Nausea (28%), vomiting (18%) Cardiovascular: Arrhythmia, bradycardia (14%), hypertension (18%), hypotension (10%), tachycardia (12%) Musculoskeletal: Chest wall rigidity (17%), skeletal muscle movements Incidence 3% to 9%; all others 1% to 3% Respiratory: Apnea , postoperative respiratory depression Central Nervous System: Blurred vision, dizziness , sleepiness/postoperative sedation Incidence Less than 1% - Probably Causally Related (Derived from clinical trials) Adverse events reported in post-marketing surveillance, not seen in clinical trials, are italicized . Body as a whole: Anaphylaxis Central Nervous System: Headache Incidence 0.3% to 1% , myoclonic movements , postoperative confusion , postoperative euphoria , shivering Dermatological: Itching , urticaria Injection Site: Pain Musculoskeletal: Skeletal muscle rigidity of neck and extremities Respiratory: Bronchospasm, hypercarbia , laryngospasm 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of alfentanil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Serotonin syndrome : Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs. Adrenal insufficiency : Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Anaphylaxis : Anaphylaxis has been reported with ingredients contained in Alfentanil Injection. Androgen deficiency : Cases of androgen deficiency have occurred with use of opioids for an extended period of time [see Clinical Pharmacology (12.2) ] . Hyperalgesia and Allodynia : Cases of hyperalgesia and allodynia have been reported with opioid therapy of any duration [see Warnings and Precautions (5.6) ] . Hypoglycemia : Cases of hypoglycemia have been reported in patients taking opioids. Most reports were in patients with at least one predisposing risk factor (e.g., diabetes). The adverse experience profile from 696 patients receiving alfentanil for Monitored Anesthesia Care (MAC) is similar to the profile established with alfentanil during general anesthesia. Respiratory events reported during MAC included hypoxia, apnea, and bradypnea. Other adverse events reported by patients receiving alfentanil for MAC, in order of decreasing frequency, were nausea, hypotension, vomiting, pruritus, confusion, somnolence and agitation.
2 DOSAGE AND ADMINISTRATION • Alfentanil Injection should be administered only by persons specifically trained in the use of intravenous anesthetics and management of the respiratory effects of potent opioids. • Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available. ( 2.1 ) • Individualize dosing based on factors such as age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used, and the surgical procedure involved. ( 2.1 ) • Doses of Alfentanil Injection vary depending on circumstances. (see dosing chart 2.2 ) • Reduce the dose of Alfentanil Injection in elderly, debilitated and obese patients. ( 2.4 , 2.5 ) • Reduce the dose of Alfentanil Injection when administered with CNS depressants. ( 2.6 ) 2.1 Important Dosage and Administration Instructions Alfentanil Injection should be administered only by persons specifically trained in the use of intravenous anesthetics and management of the respiratory effects of potent opioids. In patients administered high doses of Alfentanil Injection, it is essential that qualified personnel and adequate facilities are available for the management of postoperative respiratory depression. • Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available. • Individualize dosage based on factors such as age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used, and the surgical procedure involved. The selection of preanesthetic medications should be based upon the needs of the individual patient. • The neuromuscular blocking agent selected should be compatible with the patient's condition, taking into account the hemodynamic effects of a particular muscle relaxant and the degree of skeletal muscle relaxation required. • Patients receiving monitored anesthesia care (MAC) should be continuously monitored by persons not involved in the conduct of the surgical or diagnostic procedure; oxygen supplementation should be immediately available and provided where clinically indicated; oxygen saturation should be continuously monitored; the patient should be observed for early signs of hypotension, apnea, upper airway obstruction and/or oxygen desaturation. • Delayed respiratory depression, respiratory arrest, bradycardia, asystole, arrhythmias and hypotension have also been reported. Therefore, vital signs must be monitored continuously, including following the termination of surgery. • Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. • For purposes of administering small volumes of Alfentanil Injection accurately, the use of a tuberculin syringe or equivalent is recommended. As with other potent opioids, the respiratory depressant effect of alfentanil may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered by the practitioner before ordering opioid analgesics during recovery from anesthesia. If Alfentanil Injection is administered with a CNS depressant, become familiar with the properties of each drug, particularly each product's duration of action. In addition, when such a combination is used, fluids and other countermeasures to manage hypotension should be available [see Warnings and Precautions (5.3) ] . The physical and chemical compatibility of Alfentanil Injection have been demonstrated in solution with normal saline, 5% dextrose in normal saline, 5% dextrose in water and Lactated Ringers. Clinical studies of Alfentanil Injection infusion have been conducted with Alfentanil Injection diluted to a concentration range of 25 mcg/mL to 80 mcg/mL. As an example of the preparation of Alfentanil Injection for infusion, 20 mL of Alfentanil Injection added to 230 mL of diluent provides 40 mcg/mL solution of alfentanil. 2.2 Dosage The dosage of Alfentanil Injection should be individualized and titrated to the desired effect in each patient according to body weight, physical status, underlying pathological condition, use of other drugs, and type and duration of surgical procedure and anesthesia. The dose of Alfentanil Injection should be reduced in elderly or debilitated patients [see Warnings and Precautions (5.2) ] . See Dosing Chart for the use of Alfentanil Injection 1) by incremental injection as an analgesic adjunct to anesthesia with barbiturate/nitrous oxide/oxygen for short surgical procedures (expected duration of less than one hour); 2) by continuous infusion as a maintenance analgesic with nitrous oxide/oxygen for general surgical procedures; and 3) by intravenous injection in anesthetic doses for the induction of anesthesia for general surgical procedures with a minimum expected duration of 45 minutes; and 4) by intravenous injection as the analgesic component for monitored anesthesia care (MAC). When administering alfentanil as induction doses, administer the dose slowly (over three minutes). Because administration of the induction dose may produce loss of vascular tone and hypotension, consider given to fluid replacement prior to induction. Table 1: Dosing Chart For Use During General Anesthesia Spontaneously Breathing/Assisted Ventilation Induction of Analgesia: 8 to 20 mcg/kg Maintenance of Analgesia: 3 to 5 mcg/kg q 5 to 20 min or 0.5 to 1 mcg/kg/min Total dose: 8 to 40 mcg/kg Assisted or Controlled Ventilation - Assisted or Controlled Ventilation Incremental Injection (To attenuate response to laryngoscopy and intubation) Induction of Analgesia: 20 to 50 mcg/kg Maintenance of Analgesia: 5 to 15 mcg/kg q 5 to 20 min Total dose: Up to 75 mcg/kg Assisted or Controlled Ventilation - Continuous Infusion (To provide attenuation of response to intubation and incision) Induction of Analgesia: 50 to 75 mcg/kg Maintenance of Analgesia: 0.5 to 3 mcg/kg/min (Average rate 1 to 1.5 mcg/kg/min) Infusion rates are variable and should be titrated to the desired clinical effect. See Infusion Dosage Guidelines Below Total dose: Dependent on duration of procedure Anesthetic Induction Induction of Anesthesia: 130 to 245 mcg/kg Administer slowly (over 3 minutes). Maintenance of Anesthesia: 0.5 to 1.5 mcg/kg/min or general anesthetic. Infusion rates are variable and should be titrated to the desired clinical effect. See Infusion Dosage Guidelines Below Total dose: Dependent on duration of procedure At these doses truncal rigidity should be expected and a muscle relaxant should be utilized. In patients administered anesthetic (induction) dosages of Alfentanil Injection, it is essential that qualified personnel and adequate facilities are available for the management of intraoperative and postoperative respiratory depression. MONITORED ANESTHESIA CARE (MAC) (For sedated and responsive, spontaneously breathing patients ) Induction of MAC: 3 to 8 mcg/kg Maintenance of MAC: 3 to 5 mcg/kg q 5 to 20 min or 0.25 to 1 mcg/ kg/min Infusion rates are variable and should be titrated to the desired clinical effect. See Infusion Dosage Guidelines Below Total dose: 3 to 40 mcg/kg Patients receiving monitored anesthesia care (MAC) should be continuously monitored by persons not involved in the conduct of the surgical or diagnostic procedure Infusion Dosage Guidelines For Continuous Infusion: 0.5 to 3 mcg/kg/min administered with nitrous oxide/oxygen in patients undergoing general surgery. Following an anesthetic induction dose of Alfentanil Injection, alfentanil infusion rate requirements are reduced by 30% to 50% for the first hour of maintenance. Requirements for volatile inhalation anesthetics are also reduced by 30% to 50% for the first hour of maintenance. Changes in vital signs that indicate a response to surgical stress or lightening of anesthesia may be controlled by increasing the Alfentanil Injection to a maximum of 4 mcg/kg/min and/or administration of…
7 DRUG INTERACTIONS Table 2 includes clinically significant drug interactions with Alfentanil Injection. Table 2: Clinically Significant Drug Interactions with Alfentanil Injection Inhibitors of CYP3A4 and CYP2D6 Clinical Impact: The concomitant use of Alfentanil Injection and CYP3A4 inhibitors can increase the plasma concentration of alfentanil, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of Alfentanil Injection and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of Alfentanil Injection is achieved [see Warnings and Precautions (5.4) ] . After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the alfentanil plasma concentration will decrease [see Clinical Pharmacology (12.3) ] , resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to alfentanil. Intervention: If concomitant use is necessary, consider dosage reduction of Alfentanil Injection until stable drug effects are achieved [see Dosage and Administration (2.2) ] . Monitor patients at frequent intervals for respiratory depression and sedation. If a CYP3A4 inhibitor is discontinued, consider increasing the Alfentanil Injection dosage until stable drug effects are achieved [see Dosage and Administration (2.2) ] . Monitor for signs of opioid withdrawal. Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of Alfentanil Injection and CYP3A4 inducers can decrease the plasma concentration of alfentanil [see Clinical Pharmacology (12.3) ] , resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to alfentanil [see Warnings and Precautions (5.4) ] . After stopping a CYP3A4 inducer, as the effects of the inducer decline, the alfentanil plasma concentration will increase [see Clinical Pharmacology (12.3) ] , which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression. Intervention: If concomitant use is necessary, consider increasing the Alfentanil Injection dosage until stable drug effects are achieved [see Dosage and Administration (2.2) ] . Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider Alfentanil Injection dosage reduction and monitor for signs of respiratory depression. Examples: Rifampin, carbamazepine, phenytoin Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Diazepam administered immediately prior to or in conjunction with high doses of Alfentanil Injection may produce vasodilation and hypotension, and may result in delayed recovery. Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when Alfentanil Injection is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics. Postoperative respiratory depression may be enhanced or prolonged by these agents. Intervention: Monitor patients receiving Alfentanil Injection and benzodiazepines or other CNS depressants for hypotension patients and prolonged respiratory depression and sedation. In such cases of combined treatment, the dose of one or both agents should be reduced. Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30% to 50% for the first sixty (60) minutes following alfentanil induction [see Warnings and Precautions (5.3) ] . Examples: Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Warnings and Precautions (5.7 )]. Intervention: If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Alfentanil Injection if serotonin syndrome is suspected. Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Monoamine Oxidase Inhibitors Clinical Impact: Severe and unpredictable potentiation of monoamine oxidase (MAO) inhibitors has been reported rarely with alfentanil. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) [see Warnings and Precautions (5.8) ] Intervention: When Alfentanil Injection is administered to patients who have received MAO inhibitors within 14 days, monitor patients for hypertension and ensure ready availability of vasodilators and beta-blockers for the treatment of hypertension as needed. Examples: phenelzine, tranylcypromine, linezolid Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Clinical Impact: May reduce the analgesic effect of Alfentanil Injection and/or precipitate withdrawal symptoms. Intervention: Avoid concomitant use. Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Muscle Relaxants Clinical Impact: Alfentanil may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Intervention: Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Alfentanil Injection and/or the muscle relaxant as necessary. Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Intervention: Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed. Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Intervention: Monitor patients for signs of urinary retention or reduced gastric motility when Alfentanil Injection is used concomitantly with anticholinergic drugs. Cimetidine Clinical Impact: Cimetidine reduces the clearance of alfentanil, extending the duration of action. Intervention: Use smaller alfentanil doses for prolonged administration and monitor closely for respiratory depression and other effects of alfentanil. Nitrous oxide Clinical Impact: Nitrous oxide has been reported to produce cardiovascular depression when given with higher doses of Alfentanil Injection. Intervention: Monitor patients for signs of cardiovascular depression that may be greater than otherwise expected. • Concomitant Use of CNS Depressants : May decrease pulmonary arterial pressure and may cause hypotension. See FPI for management instructions. For postoperative pain, start with the lowest effective dosage and monitor for potentiation of CNS depressant effects. ( 5.3 , 7 ) • Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics : Avoid use with Alfentanil Injection because they may reduce analgesic effect of Alfentanil Injection or precipitate withdrawal symptoms. ( 7 )
17 PATIENT COUNSELING INFORMATION Addiction, Abuse, and Misuse Inform patients that the use of Alfentanil Injection, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [see Warnings and Precautions (5.1) ]. Life-Threatening Respiratory Depression Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting Alfentanil Injection or when the dosage is increased, and that it can occur even at recommended dosages. Hyperalgesia and Allodynia Advise patients to inform their healthcare provider if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain [see Warnings and Precautions (5.6) , Adverse Reactions (6) ]. Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition called serotonin syndrome resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop after discharge from the hospital. Instruct patients to inform their healthcare provider if they are taking, or plan to take serotonergic medications [see Warnings and Precautions (5.7) , Drug Interactions (7) ]. Constipation Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention [see Adverse Reactions (6) , Clinical Pharmacology (12.2) ].
According to its FDA label, Alfentanil is approved for: 1 INDICATIONS AND USAGE Alfentanil Injection is indicated: • as an analgesic adjunct given in incremental doses in the maintenance of anesthesia with barbiturate/nitrous oxide/oxygen. • as an analgesic administered by continuous infusion with nitrous oxide/oxygen in the maintenan… For medical advice, please talk to your prescriber or pharmacist.
Alfentanil belongs to the Opioid analgesic class of medications.
The FDA label lists Alfentanil as: 3 DOSAGE FORMS AND STRENGTHS Alfentanil Injection USP, for intravenous use (equivalent to 500 mcg/mL alfentanil base). Solution for injection (sterile): eq. to 500 mcg/mL alfentanil base; 2 mL and 5 mL ampules. ( 3 ); intravenous route. Available strengths and packaging vary by manufacturer.
Yes. The FDA label for Alfentanil carries a Boxed Warning. Excerpt: "WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ALFENTANIL INJECTION Addiction, Abuse, and Misuse Because the use of ALFENTANIL INJECTION exposes patients and other users to the risks of opioid addiction, abuse,…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.
The FDA Enforcement Report does not show an active/ongoing recall for Alfentanil in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA label lists Hospira, Inc. as a labeler/manufacturer of Alfentanil. Multiple firms may market generics of the same molecule.
The FDA label states: "Storage: Protect from light. Retain in carton until time of use. Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature]." Follow the packaging insert for the authoritative guidance.
The FDA label lists a pregnancy category of C for Alfentanil. Pregnancy and lactation decisions should be made with a clinician.
Loading full data from Know Your Drugs Institute…